Calyxo, Inc., a medical device company redefining kidney stone treatment, will arrive at the American Urological Association (AUA) Annual Meeting with strong clinical momentum, supported by an expanded evidence base and increasing adoption of the CVAC System in practice. At this year’s meeting, 10 abstracts, the highest number presented to date, will highlight safety, efficacy, and procedural efficiency, alongside multiple opportunities for hands-on, physician-led education. AUA2026 takes place May 15–18 in Washington, DC.
“We are seeing a meaningful shift in how kidney stone patients are being treated,” said Joe Catanese, PhD, Chief Executive Officer of Calyxo. “More than 40,000 patients have now been treated using the CVAC System and we continue to see how more complete stone clearance can translate into better outcomes for patients. AUA2026 is an opportunity to share the data, clinical experience, and continued product innovation that are helping physicians deliver better care.”
A Continuous Cadence of Innovation
Calyxo will showcase the latest release of the CVAC Image Processor Software (version 1.5) at AUA2026. Informed by real-world clinical use, the update enhances image clarity and consistency and integrates seamlessly into the existing workflow, supporting efficient stone clearance.
“Improved visualization makes a real difference,” said Michael A. Palese, MD, Professor and Chair of Urology, Mount Sinai Downtown and Director of Minimally Invasive Surgery at Icahn School of Medicine at Mount Sinai, who participated in the early evaluation of the software update. “Clearer, more consistent imaging enhances intraoperative visibility throughout the case, which is especially impactful during laser lithotripsy, where precision and consistency matter significantly. It helps me work more efficiently and reflects a company that partners with urologists and translates their feedback into tangible improvements.”
Scientific Presentations
Ten abstracts will be presented at AUA2026, including podium presentations highlighting safety, efficacy, and procedural efficiency of the CVAC System. Key presentations include:
Friday, May 15
Multicenter real-world outcomes of SURE with CVAC 2.0: The REASON study
Time: 3:30 PM – 5:30 PM
Location: 147B
Predictors of Procedure Efficiency in Aspiration Ureteroscopy: Insights from CVAC System Procedural Performance Database
Time: 3:30 PM – 5:30 PM
Location: 147B
Sunday, May 17
Multicenter Comparison of Stone Clearance with CVAC Aspiration Ureteroscope and Flexible and Navigable Ureteral Access Sheaths: A Role for Aspiration of Larger Stones
Time: 8:28 AM – 8:36 AM
Location: 206
The complete list of CVAC System abstracts to be presented at AUA2026 is available at https://calyxoinc.com/aua-2026-conference-calyxo-cvac/
Peer-to-Peer Educational Opportunities
Calyxo will offer multiple opportunities for physician-led education and engagement throughout AUA2026, including hands-on sessions focused on procedural technique and real-world use of the CVAC System.
Friday, May 15
11:30 AM – 11:55 AM, Booth #2161
Device Tech Talk: Are All Suction Technologies Equal? Defining High-Performance Aspiration Through the CVAC System
3:15 PM – 4:15 PM, Hands-on Training Pavilion in the Science & Technology Hall
Hands-On Workshop: Advancing Laser Techniques for High-Performance Aspiration with the CVAC System
Registration required
Saturday, May 16
11:20 AM – 11:50 AM, Main Stage Plenary Session
Semi-Live Surgical Showcase: Endourology
1:00 PM – 1:25 PM, Booth #2161
Device Tech Talk: Suction Alone Is Not Enough: Advancing Stone Clearance with the CVAC System’s High-Performance Aspiration
In-Booth Demos
AUA2026 attendees can get hands-on experience with the all-in-one CVAC System. Demonstrations are available by appointment only Friday and Saturday, 9:00 AM – 4:00 PM, and Sunday, 9:00 AM – 3:30 PM.
For a complete list of CVAC System events and data presentations or to sign-up for an in-booth demonstration, visit https://calyxoinc.com/aua-2026-conference-calyxo-cvac/
About Kidney Stones
According to the American Urological Association, approximately 10% of people in the U.S. will have a kidney stone at some point in their lives. Kidney stone disease is a painful condition that can result in significant healthcare costs (Current Urology Reports estimates $4.1 billion in annual direct treatment costs by 2030).
About the CVAC System
The CVAC System was FDA-cleared in 2024 and enables a minimally invasive approach for kidney stone clearance. It is an all-in-one solution designed to efficiently and effectively remove kidney stones. It uses irrigation and vacuum aspiration to continuously clear stone fragments during and after laser lithotripsy, enabling physicians to achieve a stone-free outcome.
About Calyxo, Inc.
Calyxo, Inc. is an innovation-driven medical device company focused on improving care for patients with kidney stones by delivering paradigm-shifting solutions that enable urologists to safely, effectively and efficiently achieve unrivaled clinical outcomes. Learn more at calyxoinc.com.
“CVAC” and “Calyxo” are registered trademarks of Calyxo, Inc.
MAC00338.A
View source version on businesswire.com: https://www.businesswire.com/news/home/20260513376663/en/
Media gallery
